Composition

• 45 researchers, engineers, technicians
• 1 Quality referent, 1 Epidemiologist, 1 Lawyer

  Facilities

• Coordinator Site (CIC-CRB 1404) :
  • CIC 1404 :
    • Site Authorization for Healthy Volunteer Trials
    • File of 1800 healthy volunteers
    • Methodological support
    • clinical trials dedicated beds with scopes
    • ECG
    • Defibrillator
    • Main access to functionnal imaging and exploration
  • Biological Resources Centre
    • Impedancemeter
    • Ultra Low Temperature Freezer (-150° and -80°C)
    • Low Temperature Freezer (-20°C and -4°C)
    • Laboratory centrifuges
    • Main access to Tumour banks (Federation of Pathology CRLCC-CHU)
• Endocrinology and Diabetology Site (U 1239) :
  • Ultra Low Temperature Freezer (-80°C)
  • Low Temperature Freezer (-20°C)
  • Laboratory centrifuges
• Neurology Site (U 1245 & U 1073):
  • Main access to diseases biomarkers
  • Functionnal imaging and exploration (MRI 3T).
  • PET imaging
  • CSF biomarkers
  • Neurosurgical team with expertise in deep brain neurostimulation
  • Site Authorization for Healthy Volunteer Trials
  • 2 polysomnography and 2 multiparameter recorders
• Nutrition Site (U 1073) :
  • Body composition through DEXA or bio-impedancemeter
  • Bone Densitometry
  • Calorimeter
  • Mass spectrometric analysis and in vivo isotopic studies
• Pediatrics Site (U 1239):
  • Ultra Low Temperature Freezer (-20°C)
  • Laboratory centrifuges
• Pharmacology Site (U 1096):
  • Clinical vascular imaging (echo-tracking, ultrasound, flattening tonometer)
  • Bio-impedancemeter
  • Site Authorization for Healthy Volunteer Trials
• Physiology Site (U 1073):
  • Digestive function investigation platform (manometry, barostat, electrophysiological studies, breath tests, gastric emptying, impedancemetry, sphincter planimetry..)
  • Digestive Neurostimulation
  • Magnetic transcranial stimulation
  • Site Authorization for Healthy Volunteer Trials
• Pneumology Site (EA 4108):
  • In vivo confocal endomicroscopy (Cellvizio®)
• Rheumatology Site (U 1234):
  • Ultrasonography
  • Bone mineral densitometry
  • Ultra Low Temperature Freezer (-80°C)
  • 6 Ultra Low Temperature Freezer (-20°C)
  • Laboratory centrifuges
  • Access to radiology department
• Urology Site:
  • Surgical robot
  • Koelis system (prostate targeted biopsies)
  • Hexvix Fluorescence (bladder cancer)
  • Chemotherapy Unit with access to immunotherapy and antiangiogenic therapies

  Activity

The Clinical Investigation Centre (Inserm-CIC 1404) and Biological Resources Centre is an ambulatory care and hospitalization Centre dedicated to clinical trials. It includes a coordinating site and 9 clinical sites (see table). The CIC-CRB 1404 was labeled as an “Inserm-CIC” in 2002, recently renewed in 2016. Research taking place in the Centre covers all medical and surgical specialties.

All types of studies are concerned: phases I to IV clinical trials, evaluation of medical devices, epidemiological, physiological and diagnostic studies. Technical resources also benefit from other several associated units facilities present within the Departments of epidemiology, Physiology, Pneumology, Endocrinology, Neurology, Nutrition, Pharmacology, Rheumatology, Urology and Pediatrics of the University hospital. The mission of the CIC-CRB 1404 is to provide facilities and resources (staff, methodology, equipment….) to researchers performing clinical studies. The CIC-CRB 1404 especially promotes translational research based on close interactions between scientists and physicians of the medical campus. Our objective is to produce new scientific and medical knowledge while ensuring compliance with ethical and legal requirements.

Since January 2021, CIC-CRB 1404 is also certified to ISO 9001 standard for its biological resources management and its investigation activities.

The CIC-CRB 1404 also participates in the training and teaching of clinical research: Master “Methods in Clinical Pharmacology and Training in Therapeutic Trials” and D.I.U. Investigator in Biomedical Research.

  Main contributions

• Institutional (65%);
• private pharmaceutical companies (35%).